GC
PPH icon

Grimes & Company’s VanEck Pharmaceutical ETF PPH Stock Holding History

Grimes & Company’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,589
Closed -$310K – 397
2024
Q4 		$310K Buy
+3,589
New +$325K 0.01% 307

Other funds holding PPH

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return

Grimes & Company's PPH Position: Q1 2025 in Review

Grimes & Company sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2025, closing a stake of 3,589 shares — an estimated $310K sold.

Grimes & Company first reported a position in PPH in Q4 2024 and held it in 1 quarter. The position peaked at $310K in Q4 2024. 136 funds tracked by Wall St. Rank hold PPH as of Q1 2025.

  • Grimes & Company reported no remaining VanEck Pharmaceutical ETF position as of Q1 2025 after selling out during the quarter.
  • Grimes & Company sold 3,589 VanEck Pharmaceutical ETF shares in Q1 2025, an estimated $310K.
  • Grimes & Company first reported a position in VanEck Pharmaceutical ETF in Q4 2024 and held it in 1 quarter.
  • Grimes & Company's VanEck Pharmaceutical ETF position peaked at $310K in Q4 2024.
  • 136 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2025.

Based on Grimes & Company's 13F filing for Q1 2025, filed 17 Apr 2025.